؉ T lymphocytes control Mycobacterium tuberculosis infection by secreting cytokines and by killing macrophages that have phagocytosed the pathogen. However, lysis of the latter cells promotes microbial dissemination, and other macrophages engulf the released bacteria. Subsequently, CD4 
Intracellular pathogens such as Mycobacterium tuberculosis
and Mycobacterium leprae are endowed with the ability to survive and proliferate within macrophage phagosomes (see Fig.  1 .25 in reference 15). In these organelles, pathogens are eventually destroyed when phagosomes fuse with primary lysosomes, which release a vast array of hydrolytic enzymes into them. However, several infections in which pathogens are phagocytosed by macrophages allow disease development, because, within the phagosome, permissive conditions develop that not only allow survival of the aggressor, but also permit its proliferation. The pathogen itself contributes to establishing such permissive conditions by impeding fusion between phagosomes and primary lysosomes (12) and by inhibiting vesicular acidification, possibly by exclusion of proton-ATPase, thus hampering the activity of lysosomal enzymes, which occurs at an acidic pH (30) .
Given all of the findings presented above, macrophages can process some of the antigen load and present it to T lymphocytes in the context of major histocompatibility complex (MHC) class II molecules. Such cells have been identified in patients with tuberculosis and tuberculoid leprosy as CD4 ϩ cytolytic T lymphocytes (13, 23) . They kill infected macrophages via Fas/Fas ligand-mediated mechanisms (29) and by perforin (or granzyme) (18) and granulysin (21) released from the secretory lysosomes of the effector cells. Mycobacteria dismissed from lysed macrophages may have reduced viability (10, 22) . However, this mechanism does not induce an efficient immune-mediated control of the disease. On the contrary, following microbial dissemination, other macrophages will engulf the released pathogens (25) , thus causing the persistency of the CD4 ϩ T-cell-mediated killing of mycobacterial antigenpresenting cells, which may hamper the pivotal role of macrophages in the control of bacterial infection.
We asked whether the subtle balance between lysis of activated macrophages by cytolytic CD4 ϩ cells and activation of cytolytic CD4
ϩ cells by activated macrophages might be maintained via an autoregulatory mechanism mediated by surface inhibitory molecules expressed on T cells. CD152 (cytotoxic T lymphocyte antigen 4 ) and CD85/leukocyte immunoglobulin-like receptor 1 (LIR-1)/immunoglobulin-like transcript 2 (ILT-2) are inhibitory receptors expressed by all T lymphocytes (27, 28) . CD152 binds CD80/ CD86 molecules on antigen-presenting cells (APCs), thus competing with the coactivation molecule CD28. In addition, its cross-linking triggers phosphatases that dephosphorylate molecules of the CD3-T-cell receptor (TCR) activation cascade (6, 19, 35) . We have shown that CD152 inhibits the specific lysis mediated by CD8 ϩ cytolytic T lymphocytes in a clonally distributed fashion (27) .
The CD85/LIR-1/ILT2 molecule belongs to the LIR/ILT family and binds to the nonclassical class I HLA-G protein (2) , to some alleles of HLA-A and -B loci (11) , and to the human cytomegalovirus UL18 gene product, a viral homolog of HLA class I (7). It is a transmembrane molecule with four immunoreceptor tyrosine-based inhibition motifs (ITIMs) in its cytoplasmic domain (8, 9) . Tyrosine phosphorylation of ITIMs creates docking sites for the SH2 domain-containing phosphatase SHP-1, which subsequently transduces an inhibitory signal by dephosphorylating and inactivating downstream tyrosine kinases (4) .
We have shown that CD85/LIR-1/ILT2 is expressed by all T lymphocytes (28) and that this molecule is detectable on the surface and in the cytoplasm of T lymphocytes by the anti-LIR-1 M402 monoclonal antibody (MAb) and in the cytoplasm by the HP-F1 MAb (28), which is less sensitive for surface immunofluorescence. Biochemical analyses of the protein and the expression of mRNA further proved that CD85/LIR-1/ ILT2 is present in all T lymphocytes. Importantly, the same study demonstrated that CD85/LIR-1/ILT2 down-regulates the antigen-specific cytolytic activity of CD8 ϩ T cells (28) . In this study, we focused on human cytolytic CD4 ϩ T cells and investigated the effects of CD152 and CD85/LIR-1/ILT2, blocked or cross-linked, on the M. tuberculosis-specific activity of cytolytic CD4 ϩ T lymphocytes. We generated CD4 ϩ T-cell clones specific for M. tuberculosis that displayed an autologous, MHC class II-restricted, lytic ability against APCs. We blocked or cross-linked the CD152 or CD85/LIR-1/ILT2 receptors by treating T cells with anti-CD152 or anti-CD85/LIR-1/ILT2 MAbs, alone or followed by goat anti-mouse (GAM) antiserum as a cross-linker, respectively. We found that blockade of the receptors increased antigen-mediated proliferation of CD4 ϩ cytolytic clones, whereas their cross-linking significantly decreased the proliferation. Next, we evaluated the lytic activity of the T-cell clones against autologous monocytes and Epstein-Barr virus (EBV)-infected B cells (B-EBV) pulsed with purified protein derivative (PPD) from M. tuberculosis, and we found that blockade of the receptors significantly increased lysis, whereas cross-linking of the receptors decreased it. Likewise, production of interleukin 2 (IL-2) and gamma interferon (IFN-␥) by CD4 ϩ cytolytic clones was strongly reduced by CD152 and CD85/LIR-1/ILT2 cross-linking. These results indicate that CD152 and CD85/LIR-1/ILT2 play a role in the regulation of the antigen-specific lytic activity of CD4 ϩ cytolytic T lymphocytes against PPD APCs.
MATERIALS AND METHODS

Generation of CD4
؉ T-cell clones. CD4 ϩ T-cell lines were obtained from five healthy donors. Peripheral blood mononuclear cells (PBMCs), isolated from heparinized venous blood by Ficoll density gradient centifugation, were cultured with PPD from M. tuberculosis (5 g/ml) in 24-well plates (Costar, Cambridge, Mass.). Human recombinant IL-2 (hrIL-2) (Pepro Tech EC, London, United Kingdom) was added on culture days 2 and 4 at a final concentration of 50 U/ml. CD4 ϩ T-cell lines were selected by repeated restimulation cycles with PPD in the presence of autologous irradiated PBMCs. Clones were generated from specific T-cell lines by plating cells at limiting dilutions of 10 cells and 1 cell/well. Phenotype and monoclonality were assessed with anti-CD3, anti-TCR-␣␤, anti-CD4, anti-CD8, and anti-V␤ MAbs (Becton Dickinson, San Jose, Calif.). MHC class II restriction of antigen recognition by the clones was probed by cytotoxicity assays in the presence of anti-MHC class II MAb (clone D1.12; a gift from R. S. Accolla, Unit of Cellular and Molecular Genetics, Advanced Biotechnology Center, Genoa, Italy).
Antibodies to inhibitory TCR. Anti-CD152 MAb (clone 4F10, ␥2a) was from Pharmingen (Hamburg, Germany). Anti-CD94 (clone HP-3B1, ␥2a) was provided by Miguel López-Botet (Servicio de Immunologia, Hospital Universitario de la Princesa, Madrid, Spain), and anti-p58. The HP-F1 MAb (␥1) was used as an anti-CD85/LIR-1/ILT2 MAb in proliferation and cytotoxicity assays. Controls of HP-F1-and anti-CD152-mediated effects on proliferation, cytotoxicity, and cytokine production were provided by MAbs specific for irrelevant mock antigens, such as anti-CD8 (clone OKT8) and anti-MHC class I (clone HB82, specific for HLA-A2, ␥2b), from the American Type Culture Collection (Rockville, Md.).
Immunophenotyping. The surface phenotype of T-cell clones was determined by flow cytometric analyses (FACScalibur; Becton Dickinson). The secondary reagent was fluorescein isothiocyanate (FITC)-labeled GAM antiserum (Southern Biotechnology Associates, Birmingham, Ala.). T cells (5 ϫ 10 4 ) were incubated with specific MAb for 20 min at 4°C. Cells were washed twice with phosphate-buffered saline (PBS), and the secondary labeled reagent was added. After incubation, cells were washed and fixed with 1% paraformaldehyde. Control cells were stained with the secondary reagent alone.
Cytoplasmic immunostaining. For the demonstration of intracellular CD85/ LIR-1/ILT2 and CD152, T cells were processed as described previously (28) . Briefly, cells were fixed for 10 min at 37°C with 4% paraformaldehyde in PBS, washed with PBS, and stained with HP-F1 MAb or anti-CD152 MAb in PBS containing 0.1% saponin. Labeling with secondary MAb was performed by addition of phycoerythrin-conjugated GAM antiserum (Southern Biotechnology Associates), and fluorescence was measured by flow cytometry. As positive controls, antibodies to MHC class I w6/32 (␥2a) and ␤-tubulin (␥1) were used. As negative controls, antibodies to CD94 (␥2a) and to KIR p-58.2 (␥1) were employed. An additional control was provided by cells stained with the secondary reagent alone.
Proliferation assays. Proliferation assays were performed by coculture of 10 Cytotoxicity assays. The ability of various MAbs to regulate the cytolytic activity of CD4 ϩ T-cell clones was measured in a conventional 4-h 51 Cr-release assay. Briefly, target cells (T) (autologous and allogeneic monocytes or B-EBV cells) were labeled for 1 h with 51 Cr (100 Ci/10 6 cells; Amersham), washed twice with PBS, resuspended in RPMI with 10% fetal calf serum, and plated in triplicate at 5 ϫ 10 3 cells/well in 96-well U-bottom plates. Effector cells (E) were plated at 5:1 effector/target (E:T) cell ratios. HP-F1 or anti-CD152 MAbs, as well as irrelevant MAbs used as controls, were included in the cytolytic assay. Crosslinking of HP-F1 or CD152 was obtained with a MAb to HP-F1 or to CD152 followed by GAM antiserum (Southern Biotechnology Associates). For redirected killing assays (27) , P815 cells (targets) were plated in triplicate in the presence of one of the following MAbs: anti-CD3, HP-F1, anti-CD152, anti-CD4, anti-CD8, or anti-MHC class II. To evaluate a possible inhibitory effect of CD85/LIR-1/ILT2 and CD152, effector cells were pretreated for 20 min at 4°C with the HP-F1 MAb and anti-CD152 MAb. P815 cells were then added to each well together with the stimulatory anti-CD3 MAb. The E:T ratio was 10:1. After 4 h, 100 l of supernatant was collected from each well and analyzed in a gamma counter for 51 Cr release. The percentage of specific lysis was calculated as [(experimental release Ϫ spontaneous release)/(maximum release Ϫ spontaneous release)] ϫ 100.
In vitro cytokine production assays. For analyses of cytokine production, culture supernatants were collected from wells at defined time points, and levels of IL-2 and IFN-␥ were measured with commercial ELISA kits (Diaclone Research, Besançon, France) according to the manufacturer's recommendations.
Statistical analysis.
Comparisons between values of cytotoxicity, cell proliferation in response to antigen, and cytokine production were performed with Student's t test. P Ͻ 0.05 was considered statistically significant.
RESULTS
Generation of human cytolytic CD4
؉ T-cell clones specific for M. tuberculosis. PBMCs were derived from five donors: three positive for the PPD skin test (namely clonesGE1, MV1, and DB1) and two negative (clones AM1 and FM1). 
TCR-␣␤
ϩ CD4 ϩ phenotype (data not shown). Clones were produced from these T-cell lines by limiting dilution. Clones were able to lyse autologous monocytes and autologous B-EBV cells pulsed with PPD. Their antigen specificity was confirmed by the inability of these clones to lyse autologous target cells not pulsed with PPD and allogeneic cells pulsed with the antigen. One clone from each of the five donors was arbitrarily selected for the study. In Fig. 1 , the cytolytic activity of CD4 ϩ T-cell clones against autologous monocytes or B-EBV cells, untreated or PPD pulsed, as well as that against allogeneic target cells is shown. Addition to the cytolytic assay of soluble anti-HLA class II MAb, which impairs presentation of the PPD peptide by HLA class II molecules, significantly inhibited lysis of PPD-pulsed targets (Fig. 1) , thus reinforcing the specificity and HLA class II restriction of the lytic function of CD4 ϩ T-cell clones. HP-F1 and anti-CD152, in addition to anti-CD3 MAb. A significant decrease in P815 lysis was observed when HP-F1 and anti-CD152 MAb were added to the assay, compared to lysis observed in the presence of anti-CD3 only. Conversely, there was no effect on lysis when control antibodies (i.e., anti-CD4, anti-CD8, and anti-MHC class II) were bound to P815 cells in addition to anti-CD3 (Table 1) . These results indicate that CD85/LIR-1/ILT2 and CD152 mediate inhibitory signals in CD3-activated cytolytic CD4 ϩ T cells.
CD85/LIR-1/ILT2 and CD152 inhibit antigen-specific proliferation of cytolytic CD4
؉ T-cell clones. We next investigated the antigen-specific functions of cytolytic CD4 ϩ T-cell clones. The role of CD85/LIR-1/ILT2 and CD152 in PPD-induced restimulation of the M. tuberculosis-specific clones was evaluated. Clones were restimulated by autologous irradiated PBMCs pulsed with PPD. Simultaneous addition in the culture of anti-CD152 MAb or of the anti-CD85/LIR-1/ILT2 MAb HP-F1, both cross-linked by GAM antiserum, inhibited proliferation, as revealed by the sharp reduction, or even absence, of cell clump formation assessed by light microscopy. [ 3 H]thymidine uptake in these samples 4 days after restimulation was significantly lower than that of control samples, with a reduction ranging from 40 to 80% (Fig. 3) . On the other hand, addition of non-cross-linked anti-CD152 or HP-F1 MAbs, which block the receptors, led to an increment of PPD-induced proliferation ranging from 30 to 70% (Fig. 3) . Controls with GAM antiserum alone, or with irrelevant antibodies used as controls (anti-CD8 and anti-MHC class I), had no effect on PPD-induced proliferation (Fig. 3) .
A follow-up of the cultures over time showed that in samples in which CD85/LIR-1/ILT2 and CD152 were cross-linked at the time of restimulation, proliferation was not restored, but instead the cells started to undergo apoptosis. As an example, DNA-content histograms of clone AM1, measured 10 days after restimulation, are shown in Fig. 4 .
CD85/LIR-1/ILT2 and CD152 inhibit the specific lysis mediated by PPD-specific CD4
؉ T-cell clones. Since PPD-specific CD4 ϩ T-cell clones are able to mediate cytolytic functions, we investigated whether cytotoxicity is modulated by CD85/LIR-1/ILT2 and CD152. When soluble anti-CD152 or HP-F1 MAbs were included in the cytolytic assay, thus blocking the activity of the receptors, a significant increase in lysis by all clones was observed with both B-EBV and monocytes as target cells (Fig.  5) . The percentage of increase in lysis ranged between 40 and 170%. On the other hand, when anti-CD152 and HP-F1 were cross-linked with GAM antiserum, a significant reduction in specific lysis was observed in 8 of 10 tests, and it ranged from 25 to 80% (Fig. 5) . In control samples, in which GAM antiserum alone or irrelevant MAbs were added to the cytolytic tests, lysis was not affected (Fig. 5) .
Cross-linked CD85/LIR-1/ILT2 and CD152 molecules downregulate IL-2 and IFN-␥ production by specific cytolytic CD4 ؉ T-cell clones. IL-2 and IFN-␥ have been shown to exert a major role in the proliferation and boosting of cytotoxic function of cytolytic CD4 ϩ T cells (31) . Accordingly, levels of IL-2 and IFN-␥ secreted by two clones 1 day after OKT3-triggered restimulation were determined (Fig. 6) . Whereas feeder cells alone did not stimulate T cells, the presence of OKT3 was sufficient to induce production of IL-2 and IFN-␥. Cross-linking of HP-F1 and anti-CD152 MAb by GAM antiserum led to inhibition of IL-2 production ranging from 30 to 92% and inhibition of IFN-␥ production ranging from 20 to 90% (Fig.  6 ). HP-F1 was more effective than anti-CD152 in the downregulation of cytokine production. In contrast, the cross-linking of irrelevant MAbs used as controls (i.e., anti-CD8 and anti-MHC class I) did not affect cytokine production (not shown).
DISCUSSION
A persistent stimulation of the immune system, such as that exerted by intracellular bacteria (e.g., Mycobacteria) or by some viruses, may lead to a dramatic expansion of specifically reactive T-cell clones that play a major role in the control of chronic infections. When uncontrolled, the cell-mediated arm of the immune defenses could determine a reduction in the diversity of the clonal repertoire due to overwhelming antigen- specific clonal expansion and to the emergence of possible autoagressive clones due to loss of tolerance (17, 32) .
It thus appears that the possibly infinite expansion of antigen-specific lymphocyte clones in response to antigens must be contained and finely tuned. Several down-regulatory mechanisms effective to this end have been recently identified. Containment of T-cell clonal expansion in response to antigens occurs via apoptosis (17) . A large number of responsive T cells in the clone will die by apoptosis independently of the clearing off of the antigen. A second down-regulatory mechanism is provided by secretion of cytokines (e.g., transforming growth factor ␤ [TGF-␤]) that down-regulate the activation or proliferation of antigen-responsive T cells (33) . A third, and possibly most efficient, way of containing an uncontrolled clonal expansion of T cells is the killing of those cells that process and present antigens (APCs) to T lymphocytes (3, 14) . Strong evidence in favor of this contention has been provided by studies of autoimmune lymphoproliferative syndromes, in which mutations of several molecules involved in the cascade leading to apoptosis (FAS, FAS-ligand, and caspases) have been described (34, 36) . It appears that APCs, which are normally killed for the containment of a cell-mediated response, survive and accumulate in the T-cell-dependent areas of peripheral lymphoid tissues where such responses occur (34) .
Finally, several groups, including our own, have shown that on the surface and in the cytoplasm of virtually all T lymphocytes, inhibitory molecules are expressed that down-regulate T-cell proliferation and effector functions, such as cytokine production and cytolysis (1, 5, 6, 27, 28) . Among these molecules, we have previously described the down-regulatory effects of the CD152 (CTLA-4) and CD85/LIR-1/ILT2 molecules on the function of CD8 ϩ T lymphocytes (27, 28) . In the study presented here, we propose a model system in which a down-regulatory role of such molecules is shown to occur in a subset of T-helper (CD4 ϩ ) human lymphocytes that exert cytotoxic functions against APCs in an antigen-specific fashion. Thus, we refer to one of the mechanisms of containment of a cell-mediated response outlined above: i.e., the killing of APCs by cytotoxic T cells. Our experiments were conducted with TCR-␣␤ ϩ /CD4 ϩ human lymphocyte clones generated by stimulation with PPD from M. tuberculosis. These antigen (PPD)-specific CD4 ϩ T-cell clones are cytolytic against targets represented by PPD-pulsed APCs (monocytes and B-EBV cells) in an antigen-specific fashion. The Th1 cytolytic phenotype of these clones was not unexpected according to studies showing that T cells from both tuberculosis-infected and uninfected subjects develop into Th1 effectors after stimulation with PPD (20, 26) . It is of note that virus-specific cytolytic CD4
ϩ T cells have also been found to lyse specifically in vitro virus-infected cells in an MHC class II-restricted fashion (24) . However, the role of these T-cell clones in the immune defense against virus-infected cells is questioned, and they are unlikely to exert relevant effector functions in vivo (24) .
In this study, we have shown that cytolytic PPD-specific CD4 ϩ T-cell clones express sets of molecules that may trigger inhibition of T-cell functions. The receptors CD152 and CD85/ LIR-1/ILT2 may be directly blocked by the appropriate MAb; alternatively, by using GAM antiserum as a second reagent, the inhibitory receptors are cross-linked and rendered active. Our previous data on cytotoxic CD8 ϩ T lymphocytes indicate that blockade of these receptors by the appropriate MAb results in increased T-cell-mediated cytolysis, whereas their cross-linking leads to a sharp decrease in such function (27, 28) .
Proliferation of the cytotoxic CD4 ϩ T-cell clones investigated herein is also regulated by CD152 and CD85/LIR-1/ ILT2 molecules, because their blockade increases T-cell proliferation, which is sharply reduced following their crosslinking. In the latter condition, we also show that T-cell apoptosis is increased and that entry into the cell cycle is reduced.
A functional down-regulation mediated by CD152 and CD85/LIR-1/ILT2 is further supported by cytotoxicity experiments in which syngeneic APC targets pulsed with PPD are challenged by the PPD-specific CD4 ϩ T-cell clones. We found that blockade of CD152 and CD85/LIR-1/ILT2 receptors significantly increased target cell lysis, while their cross-linking decreased it. The functional data also demonstrate that CD85/ LIR-1/ILT2 molecules are indeed present on the surface of cytolytic CD4 ϩ T-cell clones, although they are hardly detectable by immunofluorescence with the HP-F1 MAb. Functional assays are generally more sensitive than immunofluorescence assays and may be able to reveal the role of molecules expressed at very low density, as already proven for the CD152 molecule, which is barely found on resting T cells, but is functionally active (1, 5, 6) .
Finally, we demonstrate that the release of Th1-type cytokines (IL-2 and IFN-␥) by cytolytic CD4 ϩ T-cell clones is increased following blockade of CD152 and CD85/LIR-1/ILT2 by specific MAbs and is sharply reduced after cross-linking of these receptors by GAM antiserum.
In all functional assays, the addition of anti-CD152 and anti-CD85/LIR-1/ILT2 MAbs in combination does not significantly affect the inhibitory effect.
Some conclusions can be drawn from the data presented above. Mycobacteria are taken up by macrophages, but they survive and proliferate within these cells until the latter present antigens to cytotoxic CD4 ϩ cells. Following this interaction, macrophages may be killed by T cells. This would result in the release of still viable bacteria that could be phagocytosed by other macrophages, thus keeping the infection going. However, this phenomenon is self-limiting, suggesting that there should exist an autoregulatory mechanism to keep the fine balance between lysis of activated macrophages by cytotoxic CD4 ϩ cells and activation of cytotoxic CD4 ϩ cells by infected FIG. 6 . CD85/LIR-1/ILT2 and CD152 down-regulate IL-2 and IFN-␥ production by cytolytic CD4 ϩ T-cell clones. Twenty-four hours after restimulation of CD4 ϩ T-cell clones with OKT3 and irradiated feeder PBMCs, the amount of IL-2 and IFN-␥ in the culture medium was measured and expressed as picograms per milliliter. At the time of restimulation, HP-F1 and anti-CD152 were added to the cultures alone (blockade of receptors) or cross-linked by GAM antiserum (cross-linking of the receptors). A negative "restimulation control" was provided by T cells exposed to irradiated autologous feeder PBMCs only, in the absence of OKT3. Asterisks indicate values that are significantly different for anti-CD3, anti-CD3 plus HP-F1, anti-CD3 plus HP-F1 plus GAM, anti-CD3 plus anti-CD152, and anti-CD3 plus anti-CD152 plus GAM culture conditions. P Ͻ 0.05. macrophages. According to the results of this study, we propose that this mechanism might be regulated, at least in part, by CD85/LIR-1/ILT2 and CD152 inhibitory receptors expressed by cytolytic CD4 ϩ T cells. In a study on the effect of in vivo CD152 blockade by specific MAbs in Mycobacterium bovis BCG-infected mice, enhanced antigen-specific lymphocyte expansion and cytokine production in the draining mediastinal lymph nodes were observed (16) . However, the number of viable mycobacteria recovered from the infection sites was not affected, and no enhanced clearance of the infection was eventually observed (16) . This could be possibly due, at least in part, to the self-limiting autoregulatory mechanism suggested by the present study.
